-
公开(公告)号：US5674689A
公开(公告)日：1997-10-07
申请号：US454464
申请日：1995-05-30
IPC分类号： C12N15/09 , A61K38/00 , C07K14/72 , C07K16/26 , C12N15/12 , C12P21/08 , C12Q1/68 , G01N33/566 , C07K17/00
CPC分类号： C07K14/72 , A61K38/00 , Y10S530/81
摘要： Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.
摘要翻译： 人类降钙素受体已被克隆，测序并通过重组手段表达。 其中的受体及其抗体可用于筛选系统以鉴定人降钙素受体的激动剂和拮抗剂，从而提供治疗和预防异常骨吸收的方法以及诊断方法。
-
公开(公告)号：US5622839A
公开(公告)日：1997-04-22
申请号：US453742
申请日：1995-05-30
IPC分类号： C12N15/09 , A61K38/00 , C07K14/72 , C07K16/26 , C12N15/12 , C12P21/08 , C12Q1/68 , C12N5/10 , C12N15/63
CPC分类号： C07K14/72 , A61K38/00 , Y10S530/81
摘要： Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.
摘要翻译： 人类降钙素受体已被克隆，测序并通过重组手段表达。 其中的受体及其抗体可用于筛选系统以鉴定人降钙素受体的激动剂和拮抗剂，从而提供治疗和预防异常骨吸收的方法以及诊断方法。
-
3.发明授权
公开(公告)号：US5683884A
公开(公告)日：1997-11-04
申请号：US452802
申请日：1995-05-30
IPC分类号： C12N15/09 , A61K38/00 , C07K14/72 , C07K16/26 , C12N15/12 , C12P21/08 , C12Q1/68 , G01N33/53 , C12N15/63
CPC分类号： C07K14/72 , A61K38/00 , Y10S530/81
摘要： Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.
摘要翻译： 人类降钙素受体已被克隆，测序并通过重组手段表达。 受体及其抗体可用于筛选系统中以鉴定人降钙素受体的激动剂和拮抗剂，从而提供治疗和预防异常骨吸收的方法以及诊断方法。
-
公开(公告)号：US5674981A
公开(公告)日：1997-10-07
申请号：US453222
申请日：1995-05-30
IPC分类号： C12N15/09 , A61K38/00 , C07K14/72 , C07K16/26 , C12N15/12 , C12P21/08 , C12Q1/68 , C07K14/435
CPC分类号： C07K14/72 , A61K38/00 , Y10S530/81
摘要： Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.
摘要翻译： 人类降钙素受体已被克隆，测序并通过重组手段表达。 其中的受体及其抗体可用于筛选系统以鉴定人降钙素受体的激动剂和拮抗剂，从而提供治疗和预防异常骨吸收的方法以及诊断方法。
-
公开(公告)号：US06395740B1
公开(公告)日：2002-05-28
申请号：US09616695
申请日：2000-07-14
申请人： Nand Baindur , Virender Labroo , Steven Stroop , Stephanie Beigel , Theresa Martinez , Charles R. Petrie , Mark W. Orme , Patricia A. Mckernan , Emma E. Moore
发明人： Nand Baindur , Virender Labroo , Steven Stroop , Stephanie Beigel , Theresa Martinez , Charles R. Petrie , Mark W. Orme , Patricia A. Mckernan , Emma E. Moore
IPC分类号： A61K31495
CPC分类号： C07D295/096 , A61K31/495 , C07D295/215
摘要： Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.
摘要翻译： 描述了作为降钙素模拟物的化合物。 这些化合物可用于治疗与骨吸收相关的疾病。 本发明的降钙素模拟物中包括取代的哌嗪。 本发明的降钙素模拟物也可用于文库和用于测定降钙素受体活性的测定中。
-
公开(公告)号：US5648219A
公开(公告)日：1997-07-15
申请号：US479882
申请日：1995-06-07
申请人： Vivian L. MacKay , Emma E. Moore
发明人： Vivian L. MacKay , Emma E. Moore
CPC分类号： C12N5/0643 , C12N5/0639 , C12N2501/02 , C12N2501/39 , C12N2501/392 , C12N2503/02 , C12N2510/00 , C12N2510/04 , C12N2517/02
摘要： The present invention provides an immature dendritic cell line derived from p53 growth suppressor gene deficient animals. The immature dendritic cell line may be induced to become an activated dendritic cell line that will stimulate T-cells to proliferate. The cell line is useful for presentation of antigens involved in autoimmune disease and analysis of peptides that produce a T-cell response.
摘要翻译： 本发明提供了源自p53生长抑制基因缺陷动物的未成熟树突状细胞系。 未成熟树突状细胞系可能被诱导成激活的树突状细胞系，其将刺激T细胞增殖。 细胞系可用于介导参与自身免疫性疾病的抗原和产生T细胞应答的肽的分析。
-
公开(公告)号：US5533836A
公开(公告)日：1996-07-09
申请号：US408331
申请日：1995-03-22
申请人： Emma E. Moore
发明人： Emma E. Moore
IPC分类号： A61K38/22 , A61K31/59 , A61K38/18 , A61P19/00 , A61P19/08 , A61P43/00 , C12N5/02 , C12N5/077 , C12N5/08
CPC分类号： C12N5/0654 , A61K38/1858 , C12N2500/38 , C12N2501/135 , Y10S514/878
摘要： Methods and compositions for stimulating the growth of osteoblasts are disclosed. A composition comprising platelet derived growth factor and vitamin D is applied to osteoblasts in an amount sufficient to stimulate their growth. The methods may be used to promote the growth of osteoblasts in vitro or to promote the healing of bone defects in vivo.
摘要翻译： 公开了刺激成骨细胞生长的方法和组合物。 包含血小板衍生生长因子和维生素D的组合物以足以刺激其生长的量施用于成骨细胞。 该方法可用于促进体外成骨细胞的生长或促进体内骨缺损的愈合。
-
公开(公告)号：US06255351B1
公开(公告)日：2001-07-03
申请号：US09410115
申请日：1999-09-30
申请人： Charles R. Petrie , Patricia A. McKernan , Emma E. Moore , John M. Ostresh , Jean-Philippe Meyer , Richard A. Houghten , Clemencia Pinilla
发明人： Charles R. Petrie , Patricia A. McKernan , Emma E. Moore , John M. Ostresh , Jean-Philippe Meyer , Richard A. Houghten , Clemencia Pinilla
IPC分类号： A61K3117
CPC分类号： C07C275/28 , C07D209/20 , Y10S514/878
摘要： Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
摘要翻译： 描述了作为降钙素模拟物的二烷基脲化合物。 这些化合物可用于治疗与骨吸收相关的疾病。 本发明的降钙素模拟物也可用于测定降钙素受体活性的测定中。
-
公开(公告)号：US5830682A
公开(公告)日：1998-11-03
申请号：US770895
申请日：1996-12-13
申请人： Emma E. Moore
发明人： Emma E. Moore
CPC分类号： C12N5/0643 , C12N5/0639 , C12N5/0654 , C12N5/0657 , C12N5/0683 , C12N2501/02 , C12N2501/39 , C12N2501/392 , C12N2503/02 , C12N2510/04 , C12N2517/02
摘要： All lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes, dendritic cells, hepatocytes, myocytes and prostatic cells. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.
摘要翻译： 所有的系都是由生长抑制基因缺陷动物制备的。 细胞包括永生化前体细胞和分化细胞如破骨细胞前体，成骨细胞前体，巨核细胞，破骨细胞，成骨细胞，胰腺α细胞，胰腺β-细胞，胰腺β-细胞，脂肪细胞，巨噬细胞，软骨细胞，树突状细胞，肝细胞，肌细胞 和前列腺细胞。 细胞可用于构建cDNA和蛋白质文库，筛选化合物的激动剂和拮抗剂以及影响特定细胞的代谢途径并产生细胞特异性抗体的因子。
-
10.发明授权Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use 有权包含FGF18和IL-1拮抗剂的药物组合物及其使用方法公开(公告)号：US07749965B2
公开(公告)日：2010-07-06
申请号：US12103420
申请日：2008-04-15
申请人： Emma E. Moore , Jeff L. Ellsworth
发明人： Emma E. Moore , Jeff L. Ellsworth
CPC分类号： A61K38/1825 , A61K31/722 , A61K31/724 , A61K31/728 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
摘要翻译： 已知FGF18可刺激软骨细胞，骨骼和神经组织的增殖，导致病变组织的修复。 当除FGF18外施用IL-1拮抗剂时，发现对IL-1介导的疾病的影响以及对软骨，骨骼和神经细胞增殖的影响大于施用FGF18或IL- 1拮抗剂。 本发明包括使用该药物组合物将FGF18与IL-1拮抗剂组合的药物组合物和治疗IL-1介导的疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.034 秒)
